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a b s t r a c t
Introduction: Rifampicin (RIF) and clarithromycin (CLR) are common drugs for the treatment of infections
likeMycobacterium tuberculosis and Mycobacterium ulcerans. Treatment for these diseases are long-term and
the individual pharmacokinetic variation, drug–drug interactions or non-adherence may introduce sub-
therapeutic exposure or toxicity. The application of therapeutic drug monitoring (TDM) can be used to ensure
efﬁcacy and avoid toxicity. With the use of dried blood spot (DBS), TDMmay be feasible in rural areas. During
DBS method development, unexpected interactions or matrix effects may be encountered due to endogenous
components in the blood. Another complication compared to plasma analysis is that RIF can form chelate
complexes with ferric ions or can bind with hemes, which are potentially present in the extracts of dried
blood spots.
Methods: The investigation focused on the interaction between RIF and the endogenous components of the
DBS. The use of ethylenediaminetetraacetic acid (EDTA) and deferoxamine (DFX) as chelator agents
to improve recoveries and matrix effects were investigated. A rapid analytical method was developed
and validated to quantify RIF and CLR and their active metabolites desacetyl rifampicin (DAc-RIF) and
14-hydroxyclarythromcin (14OH-CLR) in DBS samples. A clinical application study was performed in
tuberculosis patients by comparing DBS concentrations with plasma concentrations.
Results: The interaction between RIF and the DBS matrix was avoided using the complexing agents EDTA and
DFX, which improved recoveries and matrix effects. The developed sample procedure resulted in a simple
and fast method for the simultaneous quantiﬁcation of RIF, CLR and their metabolites in DBS samples. High
stability was observed as all four substances were stable at ambient temperature for 2 months. Deming
regression analysis of the clinical application study showed no signiﬁcant differences for RIF, DAc-RIF, CLR
and 14OH-CLR between patient plasma and DBS analysis. The slopes of the correlation lines between DBS
and plasma concentrations of RIF, DAc-RIF, CLR and 14OH-CLR were 0.90, 0.99, 0.80 and 1.09 respectively.
High correlations between plasma and DBS concentrations were observed for RIF (R2¼0.9076), CLR
(R2¼0.9752) and 14OH-CLR (R2¼0.9421). Lower correlation was found for DAc-RIF (R2 of 0.6856).
Conclusion: The validated method is applicable for TDM of RIF, CLR and their active metabolites. The stability
of the DBS at high temperatures can facilitate the TDM and pharmacokinetic studies of RIF and CLR even in
resource limited areas. The role of EDTA and DFX as complexing agents in the extraction was well
investigated and may provide a solution for potential applications to other DBS analytical methods.
& 2013 Elsevier B.V. All rights reserved.
1. Introduction
Rifampicin (RIF) and clarithromycin (CLR) are used for the treat-
ment Mycobacterial infections. According to the tuberculosis (TB)
treatment guideline of the World Health Organization, RIF is the back
bone of the ﬁrst line anti-TB drugs in the treatment of Mycobacterium
tuberculosis. CLR is indicated for treatment of multidrug resistant
(MDR) TB. In combination, RIF and CLR showed high efﬁcacy for the
treatment of Mycobacterial ulcerans which is the organism causing
Buruli Ulcer disease [1]. RIF displays large pharmacokinetic variability
that may result in subtherapeutic drug exposure [2,3]. It is well known
that RIF is a liver enzymes inducer while CLR is an inhibitor. Several
studies suggested that RIF reduces the CLR plasma concentrationwhile
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CLR, on the other hand, increases the RIF plasma level [4,5]. Further-
more, the metabolism of RIF and CLR by cytochrome P450 results
in active metabolites including 25-desacetylrifampicin (DAc-RIF) and
14-hydroxyclarithromycin (14OH-CLR) [6–8]. Therapeutic drug mon-
itoring (TDM) might help to assure adequate exposure and therefore
may improve the treatment outcome of these drugs.
The common endemic areas for TB or Buruli Ulcer diseases often
have limited resources. Conventional plasma sampling is often not
feasible due to lack of equipment or cooled transportation [9]. Dried
blood spot (DBS) sampling has many potential advantages such as
prolonged sample stability, lower risk of infections and transport at
ambient temperature [9,10]. These advantages may facilitate the
application and implementation of TDM even in resource limited
areas. Methods of analysis for the determination of RIF or CLR in
the biological ﬂuids using high performance liquid chromato-
graphy (HPLC), liquid chromatography tandem mass spectrometry
(LC–MS/MS) have been reported earlier [11,12], including the simulta-
neous determination of rifampicin and clarithromycin [13,14]. Only
one report described the development of an analytical method to
determine RIF in DBS using HPLC [15]. However, the described
extraction method is time consuming, while the LLOQ of 1.5 mg/L is
still too high regarding RIF trough levels ranging from 0.2–1.0 mg/L. In
addition, the DBS method did not include the determination of DAc-
RIF. The application of LC–MS/MS with high selectivity and sensitivity
can help to deal with these limitations.
To extract DBS samples, hydrophilic or hydrophobic organic
solvents can be applied [16–18]. If hydrophilic extraction is
implemented, further liquid–liquid extraction is not required but
endogenous components from the DBS matrix will contaminate
the extract [19]. The endogenous components in the blood may
cause unexpected interactions or matrix effects during the analysis
[20]. Another complication in DBS compared to plasma analysis is
that RIF can form chelate complexes with ferric ions or can bind
with hemes which are potentially present in the extracts of dried
blood spots [21]. This could negatively affect the analytical results.
The application of ethylenediaminetetraacetic acid (EDTA) and
deferoxamine could prevent RIF from forming chelate complexes
or bind with hemes. In addition, EDTA has previously been
successfully applied to precipitate endogenous components [22].
All considered, the use of a chelator like EDTA could improve the
robustness of an analytical DBS method.
In addition to the standard validation criteria, the inﬂuence of
the hematocrit value and blood spot volume should be assessed
during the method validation, as these parameters could be of
inﬂuence on the analytical results [9,10,23]. Furthermore, before
DBS is implemented in daily routine, the correlation between RIF
in DBS and plasma concentrations should be demonstrated
[9,10,23].
The aim of this study is to develop a rapid LC–MS/MS method
for the determination of RIF, CLR and their metabolites in DBS
that is suitable for TDM or clinical pharmacokinetic studies in
rural areas.
2. Materials and methods
2.1. Chemical, reagent and disposables
Clarithromycin (C38H69NO13) and 14-hydroxyclarithromycin
(C38H69NO14) were provided by Abbott (IL, USA). Rifampicin
(C43H58N4O12) and 25-desacetylrifampicin (C41H56N4O11) were
provided by Sanoﬁ-Aventis (Frankfurt, Germany). The 2H8-Rifam-
picin and cyanoimipramine were supplied by Brunschwig Chemie
(Amsterdam, The Netherlands) and by Roche (Woerden, The
Netherlands), respectively. Puriﬁed water was prepared by a
Milli-Q Integral system (Billerica, Massachusetts, USA). Acetonitrile
(ACN) of ultra LC/MS grade were supplied by Biosolve (Valkenswaard,
The Netherlands). Disodium ethylenediaminetetraacetic acid (EDTA),
ammonium acetate, acid acetic and triﬂuoroacetic anhydride were of
analytical grade and purchased from VWR (Amsterdam, the Nether-
lands). Deferoxamine mesilate (DFX) was obtained from Novartis
Pharma (Arnhem, the Netherlands). Pooled plasma and packed red
blood cells were obtained from the Department of Hematology,
University Medical Center Groningen according to local regulations.
Whatman 31 ET CHR paper sheets (Whatman, Kent, UK) were cut
in to 46 cm2 paper cards which were used for the preparation of
calibration and quality control (QC) DBS and patient sampling.
2.2. Equipment and conditions
Vortexing was performed with a Labtek multi-tube vortexer
(Christchurch, New Zealand). Soniﬁcation was performed at 47 kHz
using a Branson 5210 ultrasonic bath (Danburry, CT, USA).
The punching machine (punch diameter of 8 mm) was supplied by
the Technical Support Facilities of the University of Leiden (Leiden, the
Netherlands) and designed by P.M. Edelbroek Ph.D., (Heemstede, the
Netherlands) and was used in an earlier study [19].
The LC–MS/MS system consisted of a Surveyors MS pump and
a Surveyor pluss autosampler connected with a Thermo Fisher
Scientiﬁc TSQ Quantum Discovery, triple quadrupole mass spec-
trometry (Thermo Fisher, Waltham, USA). The autosampler and
column were set at a temperature of 20 1C. The chromatographic
analysis was performed on a 50 mm2.1 mm3 mm HyPurity
C18 column (Interscience, Breda, the Netherlands). The analytes
were eluted with a ﬂow rate of 300 ml/min using a solvent gradient
as followed: 0–1 min, ACN from 0% to 95%, water from 95% to 0%;
1–2.5 min, ACN 95% and water 0%; 2.5–2.6 min, decreased ACN to
0% and kept eluting by 95% water until 3.5 min. The aqueous buffer
(ammonium acetate 10 g/L, acetic acid 35 mg/L and triﬂuoroacetic
anhydride 2 mg/L at pH 3.5) was kept at 5% during the gradient.
The Thermo TSQ Quantum Discovery mass selective detector
worked in positive ion mode and performed selected reaction
monitoring (SRM) at a scan width of 0.5m/z. The mass parameters
for each analytes and the internal standards are presented in
Table 1. The ion spray voltage, sheath gas pressure, auxiliary gas
pressure and capillary temperature were set at 3500 V, 35 arb
Table 1
The mass spectrometer conditions and concentrations of calibration and quality control samples.
Substance Mass transition (m/z) CE (eV) Calibration concentrations (mg/L) QC sample concentrations (mg/L)
Parent Product LLOQ LOW MED HIGH OC
Rifampicin 823.3 791.2 17 0.15, 0.45, 1.5, 3.0, 9.0, 15.0, 24.0, 30.0 0.15 0.45 15.00 24.00 60.00
Desacetyl rifampicin 781.4 749.2 14 0.15, 0.5, 1.0, 3.0, 5.0, 8.0, 10.0 0.15 0.50 5.00 8.00 20.00
Clarithromycin 748.5 590.2 18 0.05, 0.15, 0.5, 1.0, 3.0, 5.0, 8.0, 10.0 0.05 0.15 5.00 8.00 20.00
14-Hydroxy clarithromycin 764.4 606.2 20 0.05, 0.15, 0.5, 1.0, 3.0, 5.0, 8.0, 10.0 0.05 0.15 5.00 8.00 20.00
2H8-Rifampicin 831.5 799.5 17 – – – – – –
Cyanoimipramine 306.2 218.0 39 – – – – – –
CE: collision energy.
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(arbitrary units), 5 arb and 350 1C, respectively. The Xcalibur soft-
ware version 1.4 SR1 was used for peak height integration and
quantiﬁcation (Thermo Fisher, Waltham, USA).
2.3. Preparation of the samples
2.3.1. Preparation of the stock solutions
Two separate stock solutions were prepared in water at a
concentration of 600 mg/L for RIF and 200 mg/L for the other
three analytes. These stock solutions were used to prepare the
calibration curve and QC samples. For spiking low concentrations,
the stock solutions were diluted with water to 25 mg/L. This
ensures that the spiked volume of the stock solution could not
exceed 5% of the total volume. The stock solutions were stored
at 4 1C.
2.3.2. Preparation of the calibration curve and QC's in blood
The packed red blood cells (RBC) obtained from the Hematol-
ogy department contained a preservation solution. To completely
remove the preserving solution, RBC were centrifuged at 3506g for
10 min and the upper layer was discarded. To wash the RBC, an
equal volume of phosphate buffered saline with pH 7.4 was added
and mixed by a rotating mixer for 5 min. The RBC suspension was
centrifuged and the upper layer was discarded. The RBC washing
procedure was subsequently repeated twice with phosphate
buffered saline and lastly with plasma. Calibration and QC blood
at the desired Hct values were produced by mixing washed RBC
with plasma and appropriate volumes of stock solution. All the
calibration and QC blood samples were prepared at the standar-
dized Hct value of 35%, since the tuberculosis patient population
showed to have a lower mean Hct than healthy volunteers [19].
The concentrations of each component in the calibration and QC
samples are presented in Table 1.
2.3.3. Preparation of DBS Samples
The calibration and QC DBS samples were prepared by pipet-
ting 50 ml of blood onto the paper card and left to dry for 3 h at
ambient temperature. DBS cards were stored separately in sealed
plastic bags with desiccant sachets at 20 1C.
2.4. Development of the DBS extraction
The DBS at MED level were used for roughly evaluating the
process efﬁciency of different methods of extraction. The analytical
method for the simultaneous determination of RIF, CLR and their
metabolites in plasma was successfully validated previously. There-
fore, the developed DBS analytical method mainly focused on the
extraction procedure, matrix effects and recovery [14]. Different
extracting solvents including pure water, mixtures of 0%, 30% and
80% ACN in methanol were tested at a volume of 300 mL for DBS at
MED level. A sonication of 60 min at ambient temperature was used
to accelerate the extraction and 5 mL of extract was injected into the
LC–MS/MS. The sample preparation was performed in three-fold to
evaluate matrix effects and recovery in the method development
[23]. Three solutions were prepared for each extraction solvent: The
neat solution (extraction solvent) was spiked at the theoretical
calculated MED concentration (solution A). Solution A was used to
generate extracts of blank DBS (solution B). The extracts of DBS at
MED level used blank extracting solvent (solution C). The average
peak height responses were used to calculate recovery and matrix
effects. The calculations of the recovery and matrix effects were as
followed: recovery¼C/B100, matrix effect¼(B/A100)100.
The DBS aqueous extraction suffered from endogenous matrix
effects and therefore required a cleaning process [9,19]. A volume
of 600 mL ACN was added to precipitate 200 mL of DBS aqueous
extracts containing EDTA. The EDTA concentrations were tested in
the range of 0.0–1.54 g/L (12 concentrations). UV–vis absorption
spectra with a wavelength range of 200–600 nm were obtained
from the varying supernatants using a Varian UV–vis spectrometer
to indicate the cleanliness of these solutions.
2.5. Extraction procedure used for the method validation
The extracting solution consisted of 2H8-Rifampicin 0.25 mg/L
(internal standard of RIF), cyanoimipramine 0.05 mg/L (internal
standard of DAc-RIF, CLR and 14OH-CLR), EDTA 1 g/L and DFX 1 g/L
in water. A disc with a diameter of 8 mm was punched out from
the central part of DBS and transferred to a 1.5 mL Eppendorf
plastic tube. An extracting solution volume of 300 mL was added
and the extraction was accelerated by sonication for 20 min. A
volume of 200 mL of the extract was transferred to a glass vial
and a 600 mL of ACN was added to precipitate the endogenous
components. The sample was vortexed for 1 min, centrifuged at
10,146g for 5 min and 5 mL of the supernatant was injected into the
LC–MS/MS system.
2.6. Method validation
The method was validated in accordance with the US Food
and Drug Administration's Guidance for Industrial Bioanalytical
Method validation [24]. The validated criteria included the selec-
tivity, linearity, accuracy and precision, dilution integrity, carry-
over, process efﬁciency and stability. In addition to these validation
guidelines, the validation was extended with the assessment of
the inﬂuence of Hct and blood volume of DBS, which are
recommended for DBS analysis [19,25]. The validation was per-
formed with maximum tolerated bias and coefﬁcient of variation
(CV) of 20% for the lower limit of quantiﬁcation (LLOQ) and 15% for
the other validated concentrations.
2.6.1. Selectivity, speciﬁcity and carry-over
The selectivity and speciﬁcity were evaluated by comparing the
responses of the LLOQ and blank DBS samples prepared from
5 batches of human blood. The average response of blank DBS
samples was required to be within 20% of the average response of
the LLOQ samples. The carry-over was assessed using the response
ratio of a blank sample injected after a HIGH QC and compared to a
LLOQ response. The response was required to be less than 20% of
the LLOQ QC.
2.6.2. Linearity, reproducibility and dilution integrity
On each of 3 consecutive validation days, a single calibration
curve was analyzed to assess linearity. The calibration curves were
constructed using 1/x2 weighted linear regressions. The analytical
responses, which were the peak height ratios between analyte and
the respective internal standard, were used for the quantiﬁcation.
Additionally, in each validation day, ﬁve QC's of LLOQ, LOW, MED,
HIGH and OC (over the calibration curve) were analyzed in ﬁve
fold to evaluate the intra-day and inter-day accuracy and precision
and dilution integrity. The precipitated supernatants from OC
samples were diluted 10 times with extracts of blank DBS before
injection. Accuracy and the inter-day and intra-day precision was
estimated using one-way analysis of variance (one-way ANOVA).
2.6.3. Matrix effect, complexing effect and recovery
The matrix effects resulting from DBS endogenous components
or ferric chloride were evaluated at three QC levels of LOW, MED
and HIGH. The role of the complexing agents EDTA and DFX
in recovering the response due to DBS matrix effects or ferric
D.H. Vu et al. / Talanta 121 (2014) 9–17 11
Author's personal copy
chloride was also investigated. Different solutions A, B, C, D, E, F,G,
H, I and K were prepared and analyzed in ﬁve-fold as presented in
Table 2. To calculate the theoretical concentration of the neat
solution, DBS with a blood volume of 10 mL was prepared and
therefore the whole DBS could be punched for extraction. All
prepared solutions were sonicated for 20 min and 690 mL of ACN
was added to each sample. The prepared solutions yielded
volumes of 230 mL instead of the normally used volume of
200 mL. To retain the ratio of 1:3 (aqueous:ACN) for the protein
precipitation, the volume of ACN was raised to 690 mL. After
vortexing for 1 min and centrifuging at 10,146g for 5 min, the
clear solution was transferred to a glass vial and injected into the
LC–MS/MS. The mean responses of ﬁve replicate analyses obtained
from their respective solutions were denoted as A–I. The matrix
effects resulting from the DBS matrix and ferric chloride were
calculated as followed: without presence of complexing agents:
(B/A100)100 and (C/A100)100; with EDTA: (E/D100)
100 and (F/D100)100 and with the mixture of EDTA and DFX:
(H/G100)100 and (I/G100)100, where 0% represents no
decrease of signal or matrix effects. Recovery and process efﬁ-
ciency were calculated as K/I100 and K/G100, respectively,
were 100% represents optimal recovery or process efﬁciency.
2.6.4. Effect of hematocrit and blood spot volume
Hct and blood spot volume may affect the analytical results and
therefore these parameters were evaluated [19,25]. The effect of
Hct was evaluated using QC blood at three Hct values of 20%, 35%,
50%. The effect of blood spot volume was assessed by preparing
DBS with blood volumes of 30, 50 and 100 mL. At each Hct level
and blood spot volume, three QC levels of LOW, MED and HIGH
were analyzed in ﬁve-fold. The bias is calculated as the percentage
deviation from the standard Hct of 35% or blood volume of 50 mL.
Further, it was assessed if the bias caused by the Hct value could be
corrected [19].
2.6.5. Stability
The stability of the analytes in DBS was tested with QC levels
LOW and HIGH after storing at temperatures of 50 1C for 1, 3, 7
and 15 days, at 37 1C for 10, 20 and 30 days and at ambient
temperature for 7, 30 and 60 days. The samples were prepared and
analyzed in ﬁvefold and the analytical result was compared with
their nominal concentration.
2.7. Clinical application study
Adult tuberculosis patients in the TB unit of the Beatrixoord
hospital who received rifampicin or clarithromycin were eligible
for the clinical application study. The proposal was approved by
the medical ethical committee of University Medical Center
Groningen. Informed consents were obtained from all participat-
ing patients. To create a ﬁnger prick, the patient's ﬁnger was
disinfected with 70% ethanol and, after the ethanol completely
evaporated, a prick was made with a disposable contact activated
lancet (Becton Dickinson, New Jersey, United States). A single drop
of blood was deposited on a coded paper card. Three DBS samples
at 0, 2 and 8 h after dosing for clarithromycin or at 1,2 and 4 h after
dosing for rifampicin were collected from each patient. The DBS
samples were then left to dry at ambient temperature for 3 h and
stored separately in a sealed plastic bag with a desiccant sachet
at 20 1C until analysis. A venous blood sample was taken
at the same time as DBS sampling using an EDTA vacutainer. After
centrifuging for 5 min at 3506g, the plasma was obtained and
stored at 20 1C until analysis with a validated method [14,26].
The correlation between DBS and plasma analytical results were
assessed using simple linear regression and Deming regression to
compare the analyte concentrations in plasma and DBS samples by
applying the software tool Analyze-it, version 2.20 (Analyze-it
Software, Ltd.) in Microsoft Excel.
Table 2
Experimental design to investigate the matrix effect, complexing effect, recovery and process efﬁciency.
Added components Solutionsa
A (mL) B (mL) C (mL) D (mL) E (mL) F (mL) G (mL) H (mL) I (mL) K (mL)
Neat solution 200 200 200 200 200 200 200 200 200
Ferric chloride 1 g/L 10 10 10
EDTA 23 g/L 10 10 10 10 10 10 10
Deferoxamine 23 g/L 10 10 10 10
Blank DBS (disc) 1 1 1
QC DBS (disc) 1
Water 30 20 30 20 10 20 10 10 210
Neat solution: aqueous solution containing the analytes at the theoretical concentrations of LOW, MED and HIGH level; QC DBS (disc): DBS at LOW, MED and HIGH
concentrations.
a These solutions were subsequently processed according to the described extraction procedure, with the added volume of 690 mLACN.
Table 3
Effect of different extracting solutions on matrix effects and recovery at MED level.
Extracting solution (ACN: MeOH) Rifampicin Desacetyl rifampicin Clarithromycin 14-Hydroxy clarithromycin
Matrix effect (%) 0:100 85 37 6 9
30:70 81 26 12 13
80:20 83 41 3 3
Recovery (%) 0:100 40 54 75 68
30:70 32 44 65 59
80:20 2 1 3 2
Data calculated from 3 replications.




The extraction of DBS was intensively investigated by testing
various extraction solvents. With the use of methanol or its
mixture with ACN, a dramatic decrease in peak height of rifampi-
cin was observed. The addition of ACN appeared to negatively
inﬂuence the recovery. With 80% of ACN in methanol, recoveries of
less than 3% for all four analytes were observed (Table 3).
During method development it was observed that the rifampi-
cin peak height decreased in the presence of DBS extracts or whole
blood matrix. The same effect was observed if ferric chloride was
added to the neat solution at a ﬁnal concentration of 50 mg/L in
the extract. The assumption is that rifampicin may bind with
components in the DBS matrix in which Fe3þ was suggested to be
a potential factor [22]. Therefore, the un-fragmented mass of RIF-
Fe(III) (m/z¼879, collision energy¼0 eV) was checked and a small
peak at the retention time of rifampicin was observed. The efforts
to adjust the chromatographic conditions did not succeed to
retrieve the chromatographic response of rifampicin. In addition,
complexing agents such as EDTA and DFX could not prevent the
formation of these complexes during the extraction when metha-
nol or ACN was used.
The aqueous extraction of DBS yielded a dark red extract which
was not suitable to directly inject into LC–MS/MS system. The
addition of ACN and methanol to the aqueous extracts did not
sufﬁciently precipitate the endogenous components. However, the
use of an aqueous extracting solution containing EDTA can initiate
the precipitation of endogenous components. With the EDTA
concentration range from 0 to 1.54 g/L, the precipitation depended
on the EDTA concentration. As the concentration of EDTA
increased, the amount of precipitated endogenous components
in the DBS increased and therefore the supernatant was cleaner. At
an EDTA concentration higher than 0.58 g/L, the precipitated
extracts appeared to be totally colorless and UV–vis spectra
presented no signiﬁcant absorbance peak (Fig. 1). Although the
EDTA concentration of 0.58 g/L was sufﬁcient to precipitate endo-
genous components in the DBS, the EDTA concentration of 1 g/L
was used to compensate for potential patient variability in blood
characteristics. The precipitation of endogenous components from
the aqueous extracts of DBS using EDTA and ACN was simple, rapid
and can be applied to analysis methods for other drugs also.
Although the precipitated extraction was optically clean with the
presence of EDTA, the peak height of rifampicin was approximately
50% of the peak height of respective neat solution. It was recovered to
approximately 100% after adding DFX to the extracting solution at a
ﬁnal concentration of 1 g/L.
3.2. Method validation
3.2.1. Selectivity, speciﬁcity and carry over
The mean response of the blank samples accounted for less
than 4.6% of the response of LLOQ samples. In addition, all six
batches of human blood showed no signal higher than 20%
response of the LLOQ sample prepared from the same matrix. A
corresponding chromatogram is presented in Fig. 2. No carry-over
was observed for all four analytes as the responses of the blank
sample after injecting a HIGH QC sample were less than 20% of the
response of LLOQ samples.
3.2.2. Linearity, reproducibility and dilution integrity
The calibration curves of RIF, DAc-RIF, CLR and 14OH-CLR
showed to be linear with correlation coefﬁcients (R2) of 0.9953,
0.9971, 0.9987 and 0.9986, respectively. The linear model test
based on ANOVA showed no signiﬁcant lack of ﬁt. The CV and bias
(n¼3) at each calibration level were all less than 15%.
The reproducibility of the method was assessed as the accuracy
and the within day and between day precision. The accuracy and
precision estimated by one-way ANOVA analysis were tolerated with
criteria of the FDA guidelines in which acceptable bias and CV are
less than 20% for LLOQ and 15% for other validation concentrations
(Table 4).
The accuracy and precision of the 10 times diluted OC samples
were within the acceptance of FDA guidance demonstrating the
dilution integrity of the method (Table 4).
3.2.3. Matrix effect, complexing effect and recovery
With the presence of ferric chloride or DBS, substantial matrix
effects of at least 72% were observed, which resulted in a
dramatic decrease in peak heights of RIF. This effect was neutra-
lized by incorporating complexing agents during the extraction.
With the presence of EDTA and DFX, the observed matrix effects
due to DBS were þ2%, þ6% and 4% for the LOW, MED and HIGH
levels of RIF respectively. Similar matrix effects of at least 48%
were observed with DAc-RIF. The used complexing agents reduced
the matrix effects. However, the matrix effects were not fully
excluded as 11% to 33% matrix effects were still observed in
DBS. The responses of CLR and 14OH-CLR were not inﬂuenced by
the DBS matrix or the presence of the complexing agents. High
recoveries of 88–102% were obtained at three QC levels for CLR
and 14OH-CLR. Lower recoveries of RIF and DAc-RIF between 70%
and 91% were observed yielding lower process efﬁciencies. Never-
theless, compared to methanol or its mixtures with ACN the
aqueous extraction with the use of EDTA and DFX produced 51%
higher recoveries for RIF and 31% higher recoveries for DAc-RIF at
the MED levels (Tables 3 and 5).
3.2.4. Effect of hematocrit and blood spot volume
At all three QC levels of CLR and 14OH-CLR, Hct of 20% and 50%
generated minor bias, which was within the acceptance limit of 15%.
For RIF and DAc-RIF however, a bias of -18.4% was observed at a Hct
of 20% and a bias of 28.0% was observed for a Hct of 50%. When the
analytical results were corrected for their respective Hct value
according to Vu et al. [19], the biases were reduced to 8.9% and
15.8% respectively.
The variation in blood spot volume resulted in from 7.8% to
8.9% for all four analytes at QC MED and HIGH. At LOW QC the
blood spot volume of 30 mL resulted in negative biases as low as
Fig. 1. UV–vis absorbance of the precipitated DBS extracts using different EDTA
concentrations. A: ACN: water (v/v 3:1); B: Blank extract using EDTA 1.54 g/L in
water; C: Extracts of DBS using EDTA concentrations of 0–0.38 g/L in water; D:
extracts of DBS using EDTA concentrations of 0.58–1.54 g/L in water.
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23.6, 19.4, 17.6 and 20.6% for RIF, DAc-RIF, CLR and 14OH-CLR,
respectively.
3.2.5. Stability
A high stability was observed with CLR and 14OH-CLR in DBS in
which no signiﬁcant degradation occurred at ambient tempera-
ture, 37 1C and 50 1C for 60 days, 30 days and 15 days, respectively.
RIF and DAc-RIF showed to be stable at ambient temperature for
up to 2 months. At higher temperatures of 37 1C and 50 1C, RIF and
DAc-RIF were stable for 10 days and for 3 days, respectively.
Longer storage at temperatures over 37 1C resulted in more than
15% degradation (Table 6).
3.3. Clinical application study
Thirteen patients receiving rifampicin agreed to join the study.
One patient experienced vomiting on the sampling day and was
Fig. 2. Representative chromatograms; A: LLOQ DBS sample; B: DBS sample of a TB patient at t¼2 h after administered rifampicin (DBS concentration RIF¼11.00 mg/L,
DAc-RIF¼0.51 mg/L); C: B: DBS sample of a TB patient at t¼2 h after administered clarithromycin (DBS concentration CLR¼0.80 mg/L, 14OH-CLR¼0.92 mg/L).
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excluded. From the remaining twelve patients, eight pairs had RIF's
concentrations under LLOQ (0.2 mg/L for plasma and 0.15 mg/L for
DBS) both in plasma and in DBS. The DAc-RIF concentrations lower
than LLOQ (0.2 mg/L for plasma and 0.15 mg/L for DBS) were
observed in 16 pairs of samples. Two pairs of samples with DAc-
RIF concentrations above LLOQ for DBS (0.19 mg/L and 0.23 mg/L)
but below LLOQ for plasma were not included in the regression
analysis. Four MDR-TB patients treated with CLR provided 12 pairs
of DBS and plasma samples. Under LLOQ levels (0.1 mg/L for plasma
and 0.05 mg/L for DBS) were observed in two pairs of samples of
CLR and 14OH-CLR. The correlation results obtained with Deming
regression are shown in Fig. 3. The slopes of the correlation lines
between DBS and plasma concentration of RIF, DAc-RIF, CLR and
14OH-CLR were 0.90, 0.99, 0.80 and 1.09 respectively.
4. Discussion
The result of this study revealed that concentrations of RIF, CLR
and their active metabolites can be measured in DBS which
present a good correlation with plasma. Therefore, this method
is considered suitable for therapeutic drug monitoring and phar-
macokinetic studies. The validated analytical method was repro-
ducible and and the DBS specimens showed high stability. In
Table 4
Accuracy, precision and the dilution integrity (n¼5).
QC level Rifampicin Desacetyl rifampicin Clarithromycin 14-Hydroxy clarithromycin
LLOQ LOW MED HIGH OC LLOQ LOW MED HIGH OC LLOQ LOW MED HIGH OC LLOQ LOW MED HIGH OC
Nominal concentration (mg/L) 0.15 0.45 15.0 24.0 60.0 0.15 0.5 5.0 8.0 20.0 0.05 0.15 5.0 8.0 20.0 0.05 0.15 5.0 8.0 20.0
Accuracy (% bias) 1.1 1.9 1.6 0.5 4.0 0.1 5.0 1.4 0.1 12 0.3 10.5 3.6 0.2 4.0 3.9 4.7 4.7 2.7 7
Within-run precision (% CV) 5.4 2.1 3.2 2.7 3.8 12.5 6.0 4.8 4.2 4.1 9.1 3.7 2.6 2.3 3.2 10.7 5.6 3.4 3.3 3.2
Between run precision (% CV) 7.2 2.6 2.4 3.7 6.2 11.0 4.8 0.0 0.0 7.1 0.0 4.8 0.6 0.0 5.9 6.4 7.9 3.7 0.0 6.2
Overall precision (% CV) 9.0 3.3 4.0 4.6 7.3 16.6 7.7 4.8 4.2 8.2 9.1 6.0 2.7 2.3 6.7 12.5 9.7 5.0 3.3 7.0
OC: Over the calibration curve concentration (diluted 10 times).
Table 5
Matrix effects, complexing effects, recoveries and process efﬁciencies.
Matrix Calculation
formulaa


























(1) Ferric chloride (B/A100)100 72 83 83 48 52 49 5 15 15 6 1 2
(2) DBS (C/A100)100 40 66 72 32 47 50 2 6 1 15 7 9
(3) Ferric chloride with EDTA (E/D100)100 32 4 9 58 33 14 17 10 8 4 4 6
(4) DBS with EDTA (F/D100)100 58 58 63 59 62 49 6 14 11 22 4 2
(5) Ferric chloride with EDTA and
DFX
(H/G100)100 3 8 9 31 13 4 9 10 3 5 7 4
(6) DBS with EDTA and DFX (I/G100)100 2 6 4 33 22 11 0 3 2 15 3 1
(7) Recovery K/I100 70 91 87 70 85 82 99 102 95 88 92 90
(8) Process efﬁciency K/G100 71 96 83 47 66 73 99 105 98 75 89 90
(1) Decrease of the signal with the presence of ferric chloride, (2) Matrix effect of DBS without the presence of ferric chloride, EDTA or DFX, (3) Decrease of the signal by the
effect of ferric chloride and EDTA, (4) Matrix effect of DBS with the presence of EDTA, (5) Decrease of the signal by the effect of ferric chloride in the presence of EDTA and
DFX, (6) Matrix effect of DBS with the presence of EDTA and DFX, (7) Recovery with the presence of EDTA and DFX, (8) Process efﬁciency with the presence of EDTA and DFX.
Row 1 to 6 should be 0% when no decrease of signals, or matrix effects were observed.
Row 7 and 8 should be 100% when recoveries and process efﬁciencies were optimal.
a Calculations are based on the mean of ﬁve-replicated samples of the respective solutions; Parameters A–K used in the calculation formulas are derived from Table 2.
Table 6
Long term stability under different storage temperature (n¼5).
Temperature Time (days) Rifampicin Desacetyl rifampicin Clarithromycin 14-Hydroxy clarithromycin
LOW HIGH LOW HIGH LOW HIGH LOW HIGH
Ambient 7 5.5 (4.3) 0.6 (3.4) 1.2 (12.7) 1.1 (5.9) 4.8 (7.7) 2.4 (3.8) 9.2 (9.7) 4.3 (3.3)
30 2.6 (5.2) 1.7 (2.6) 2.4 (3.2) 0.6 (5.7) 9.2 (3.8) 0.1 (3.8) 4.5 (5.2) 2.1 (5.0)
60 4.3 (2.4) 14.5 (2.2) 3.3 (4.5) 11.5 (5.0) 7.8 (4.8) 5.5 (1.8) 3.0 (8.9) 3.0 (3.9)
37 1C 10 0.6 (4.1) 14.1 (3.4) 4.8 (5.8) 11.1 (1.7) 10.7 (6.3) 7.0 (3.2) 1.4 (3.3) 0.6 (1.5)
20 8.9 (5.8) 19.2 (1.7) 8.0 (7.1) 20.3 (2.5) 8.0 (6.1) 7.7 (4.8) 1.7 (4.5) 6.4 (4.5)
30 15.0 (6.8) 28.2 (5.3) 15.7 (8.9) 26.4 (4.0) 13.9 (6.5) 6.7 (3.4) 0.2 (5.7) 4.4 (3.4)
50 1C 1 1.2 (6.0) 0.8 (2.6) 5.8 (6.4) 3.2 (3.7) 8.2 (4.1) 0.8 (2.6) 1.5 (4.9) 3.6 (1.4)
3 9.8 (4.7) 9.1 (2.1) 11.9 (7.3) 5.5 (5.0) 0.7 (4.1) 3.9 (1.2) 5.7 (5.2) 8.8 (2.8)
7 15.7 (4.5) 19.0 (5.5) 18.4 (10.1) 14.0 (5.3) 2.0 (2.8) 0.0 (5.0) 5.0 (2.6) 6.0 (7.0)
15 20.2 (5.0) 24.2 (5.4) 31.3 (12.2) 25.8 (7.0) 9.4 (4.4) 1.9 (3.8) 6.9 (6.4) 1.1 (3.0)
Results are presented as % Bias (% CV) of ﬁve replications. The bias was calculated from the nominal concentration.
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addition, a simple extraction was developed in which problems
due to the interaction between the analytes and the DBS matrix
was minimized.
The development of a simple extraction method was challenged
by low recoveries and substantial matrix effects observed for RIF and
DAc-RIF during extraction with ACN, methanol or their mixtures.
Consequently, in the pre-validation experiment, non-linear calibra-
tion curves and irreproducible results were observed. Experiments
during method development revealed that signiﬁcant matrix effects
occurred if DBS or blood was added to the extraction. The complex
formation between RIF and endogenous components in blood
extracts was assumed in a previous suggested theory [21,22]. This
complex was unstable and showed to have a slightly different
retention time. During ionization, the analytes were released from
their complexes. A shoulder was observed next to the RIF and
DAc-RIF's peak and thus deteriorating the chromatographic quality
of the analysis and lowering the peak height at the RIF's retention
time. The incorporation of complexing agents such as EDTA and DFX
aimed to prevent the formation of these complexes during the
extraction was unsuccessful with the extraction using methanol or
ACN. During method development it was observed that an aqueous
extraction provided an appropriate environment for interaction
between the DBS matrix and complexing agents. Furthermore, EDTA
added to the aqueous extraction solvent improved the precipitation
of the DBS extract, resulting in a cleaner supernatant. Without EDTA,
the response of RIF and DAc-RIF was negatively inﬂuenced by
the dirty extract while no such effect was observed with CLR and
14OH-CLR. Interestingly, the efﬁcacy of the precipitation appeared to
be EDTA concentration-dependent. An EDTA concentration higher
than 0.58 g/L showed to be sufﬁcient for a good precipitation. The
incorporation of EDTA recovered the response of the neat RIF's
solution containing ferric chloride but not of the DBS extract, were
the complexing effects were again strongly present at 58% to
63%. It was supposed that RIF may interact with other endogenous
Fig. 3. Clinical application study of venous blood and DBS for rifampicin, desacetyl rifampicin, clarithromycin and 14 hydroxy clarithromycin. The dotted line is the identity
line, the continuous line is the Deming regression line. Simple linear regression coefﬁcients and Deming regression equations are the following. rifampicin: R2¼0.9076
(n¼28), y¼0.90x0.01 (95% conﬁdence interval (CI) slope: 0.78–1.01, intercept: 0.53–0.51); desacetyl rifampicin: R2¼0.6856 (n¼19), y¼0.99xþ0.06 (95% CI slope: 0.46–
1.52, intercept: 0.20–0.32); clarithromycin: R2¼0.9752 (n¼10), y¼0.80x0.15 (95% CI slope: 0.53–1.08, intercept: 0.41–0.11) and 14 hydroxy clarithromycin: R2¼0.9421
(n¼10), y¼1.09x0.13 (95% CI slope: 0.81–1.37, intercept: 0.29–0.03).
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components in the DBS matrix rather than only the ferric ions. It was
reported that DFX as a ferric chelating agent improves the analytical
response of artemisinin derivatives [27]. The addition of both DFX
and EDTA to the extraction solutions recovered the responses of RIF
in the DBS extraction to approximately 100% (Table 5). The successful
combination of EDTA and DFX for the extraction might be explained
by their chelating properties. During the complex formation DFX
completely covers the surface of Fe3þ , while EDTA is not able to
completely shield the surface of the Fe3þ ion and forms an open
(basket) complex. Although EDTA has a high stability constant for the
formation of the EDTA and Fe3þ complex, other metal ions also form
complexes with EDTA, making EDTA not a very speciﬁc chelating
agent. DFX on the other hand, is known for its strong binding afﬁnity
to Fe3þ and less afﬁnity to other metals, making it a speciﬁc
chelating agent for Fe3þ . This makes DFX better suitable as a
complexing agent. However, the contribution of EDTA in the devel-
oped method is 2-fold. First, it can form complexes with Fe3þ .
Second, it aids in the precipitation of dissolved matrix after the DBS
extraction which is performed by the addition of ACN [28].
The DBS sampling without a volumetric device is confronted with
an analytical bias resulting from the variation of Hct or blood volume
of the spot. It is generally known that as Hct values increase, and thus
viscosity of the blood, DBS will become smaller and higher concen-
trations will be measured for the same ﬁxed area punch. On the
other hand, lower concentrations will be measured in ﬁxed size spots
at lower Hct values. As expected, this study also showed signiﬁcant
biases at the extreme Hct values. The correction for the Hct value can
reduce this bias to an acceptable range [19]. Since the Hct values of
patients may not be available for this correction, the bias up to 28%
for RIF should be taken into account when interpreting analytical
results to make a clinical decision. Similarly, biases of approximately
20% were observed with the blood spot of 30 μL at LOW QC
concentration. This may result from a chromatographic effect in
which the analytes stay more in the centre part of the DBS. As an
acceptance criterion for the approval of a DBS during routine analysis,
a minimal spot size, corresponding with a 50 mL DBS, should be
applied. The use of a volumetric capillary may be considered to
reduce this kind of bias [10,23].
The clinical application study showed no signiﬁcant differences
between patient analysis of plasma and DBS for RIF, DAc-RIF, CLR and
14OH-CLR. The slope of CLR (0.80) showed the highest deviation
from the identity line, indicating a systematic difference between
plasma and DBS. The 95% conﬁdence intervals of the Deming
regression analysis showed no signiﬁcant deviation from the ideal
correlation. For CLR, the differences in concentrations between
plasma and DBS can be clinically relevant, and based on the current
results it is advised to compensate for these differences with the use
of the Deming ﬁt correlation equation. Although DAc-RIF showed no
systematic difference between plasma and DBS, the correlation
coefﬁcient had a low R2 of 0.6856. This may result in substantial
errors once plasma exposure is predicted from DBS concentrations.
Since DAc-RIF is equally active as RIF, the sum of both concentrations
can be used to evaluate whether patient concentrations are within
therapeutic range. However, DAc-RIF concentrations are about ten-
fold lower than their respective RIF concentrations, and will therefore
be less likely to affect potential dose adjustments based on TDM. It
was noticed that DBS and plasma samples under LLOQ levels were
100% matched for CLR, RIF and 14OH-CLR and 89% matched for DAc-
RIF. These results showed that DBS sampling can also be useful to
monitor the non-adherence of patients or patients with very low
bioavailability. The results of DBS as a consequence can be used to
predict the plasma exposure which is well investigated in pharma-
cokinetics studies. However, it would be advisable to assess a larger
population for an extended clinical application study in the future.
One of the most attractive issues of DBS in bioanalysis is the
stability. This study showed that RIF, CLR and metabolites were stable
up to 2 months at ambient temperature of approximately 25 1C. All
four substances also showed to be stable at 37 1C, which mimics a
tropical climate and is common in the high burden areas like South
Africa and Asia. In these conditions, CLR and 14OH-CLR were not
affected after 2 months and RIF and DAc-RIF were stable after 10 days
of storage only. CLR and its metabolite 14OH-CLR also showed a high
stability at a high temperature of 50 1C as no signiﬁcant degradation
was observed after 15 days. RIF and its metabolite DAc-RIF showed to
be stable after 3 days of storage at 50 1C. Although RIF and DAc-RIF
were found to be less stable than CLR, 10 days at 37 1C or 3 days at
50 1C could be enough for transporting sample even by normal post.
In conclusion, a rapid LC–MS/MS method was developed and
thoroughly validated to simultaneously quantify RIF, CLR and their
metabolites in DBS. The role of EDTA and DFX as complexing agents
in the extraction was well investigated and may provide
a solution for potential applications to other DBS analytical methods.
The clinical application study showed a good correlation between the
results of DBS and conventional sampling. The long term stability of
the DBS at high temperature could facilitate the TDM and pharma-
cokinetic studies of RIF and CLR even in resource limited areas.
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